Biogen Inc (NASDAQ:BIIB) EVP Alfred Sandrock sold 743 shares of the stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $292.00, for a total transaction of $216,956.00. Following the completion of the sale, the executive vice president now directly owns 6,553 shares of the company’s stock, valued at approximately $1,913,476. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
Alfred Sandrock also recently made the following trade(s):
- On Thursday, February 15th, Alfred Sandrock sold 1,294 shares of Biogen stock. The shares were sold at an average price of $298.85, for a total transaction of $386,711.90.
Shares of Biogen Inc (NASDAQ:BIIB) opened at $284.81 on Friday. Biogen Inc has a fifty-two week low of $244.28 and a fifty-two week high of $370.57. The firm has a market cap of $60,528.09, a price-to-earnings ratio of 23.89, a PEG ratio of 1.49 and a beta of 0.75. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.34 and a quick ratio of 2.07.
Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Thursday, January 25th. The biotechnology company reported $5.26 earnings per share for the quarter, missing the Zacks’ consensus estimate of $5.44 by ($0.18). Biogen had a net margin of 20.69% and a return on equity of 38.32%. The firm had revenue of $3.31 billion during the quarter, compared to analyst estimates of $3.08 billion. During the same quarter in the previous year, the business posted $5.04 earnings per share. Biogen’s revenue for the quarter was up 15.1% compared to the same quarter last year. sell-side analysts anticipate that Biogen Inc will post 24.88 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently made changes to their positions in BIIB. Tributary Capital Management LLC raised its holdings in shares of Biogen by 21.2% in the 3rd quarter. Tributary Capital Management LLC now owns 2,000 shares of the biotechnology company’s stock valued at $626,000 after purchasing an additional 350 shares in the last quarter. Oakbrook Investments LLC raised its holdings in shares of Biogen by 321.2% in the 3rd quarter. Oakbrook Investments LLC now owns 52,970 shares of the biotechnology company’s stock valued at $16,586,000 after purchasing an additional 40,395 shares in the last quarter. LS Investment Advisors LLC raised its holdings in shares of Biogen by 4.1% in the 3rd quarter. LS Investment Advisors LLC now owns 6,545 shares of the biotechnology company’s stock valued at $2,049,000 after purchasing an additional 258 shares in the last quarter. Farmers & Merchants Investments Inc. raised its holdings in shares of Biogen by 4.1% in the 3rd quarter. Farmers & Merchants Investments Inc. now owns 18,257 shares of the biotechnology company’s stock valued at $5,717,000 after purchasing an additional 723 shares in the last quarter. Finally, Barometer Capital Management Inc. acquired a new stake in shares of Biogen in the 3rd quarter valued at $5,166,000. Institutional investors and hedge funds own 89.20% of the company’s stock.
Several analysts have recently weighed in on the stock. BMO Capital Markets reissued a “buy” rating on shares of Biogen in a research note on Thursday, January 25th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Biogen in a research report on Thursday, February 8th. Canaccord Genuity increased their price objective on shares of Biogen from $340.00 to $350.00 and gave the stock a “hold” rating in a research report on Wednesday, January 24th. Oppenheimer increased their price objective on shares of Biogen from $380.00 to $400.00 and gave the stock a “buy” rating in a research report on Friday, January 26th. Finally, Royal Bank of Canada increased their price objective on shares of Biogen to $347.00 and gave the stock a “sector perform” rating in a research report on Friday, January 26th. Ten investment analysts have rated the stock with a hold rating and twenty-three have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $368.99.
ILLEGAL ACTIVITY NOTICE: “Alfred Sandrock Sells 743 Shares of Biogen Inc (BIIB) Stock” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/23/alfred-sandrock-sells-743-shares-of-biogen-inc-biib-stock.html.
Biogen Company Profile
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.